“Psychedelic drugs are integrating into our society at breakneck speed. Psychedelics are a huge rising star in the drug therapy industry, and ‘there’s almost no mental health condition right now that’s not being looked at.’ That’s because mental health issues currently are costing the global economy $1 trillion per year. Consequently, numerous large organizations, schools, and companies are studying the use of psychedelics for such conditions as mood and substance use disorders, PTSD, opioid addiction, alcohol and cancer issues, Alzheimer’s, end-of-life fears, anorexia nervosa, and major depression, among other areas. In 2019, Johns Hopkins University opened the first-of-its-kind Center for Psychedelic and Consciousness Research. They also have published ‘groundbreaking studies in more than 60 peer-reviewed articles in respected scientific journals. This makes Johns Hopkins the leading psychedelic research institution in the U.S., and among the few leading groups worldwide.’ The Center’s opening fortuitously corresponded with the FDA’s ‘breakthrough therapy’ classification for psilocybin. This new classification helps fast-track the approval of promising pharmaceuticals, of which psilocybin is major. ‘The psychedelic pharma market is currently a little over $2 billion and is expected to be valued at more than $6.8 billion by 2027. I believe that the future of psychiatry will find psychedelic medicine at its heart’ (Alex Belser, Ph.D.). While psychedelic ‘therapy’ focuses on non-directive support of a patient’s inner experience and is wrapped in psychological jargon, it’s the same method shamans and sorcerers use to contact spirits and gain supernatural power.”
Psychedelic Seduction: Drugging the World and the Church by Richard and Linda Nathan, available from lighthousetrailsresearch.com